

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 3

Complete if Known

Application Number	10/566,823
Filing Date	Herewith
First Named Inventor	Ping Wang
Art Unit	To Be Determined
Examiner Name	To Be Determined
Attorney Docket Number	KLBS0009-100

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication/Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
JH	AA	US-2002/0122818	09-05-2002	Albani	
	AB	US-2002/0122820	09-05-2002	Hildebrand et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date/Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
JH	AC	EP 0 356 340	02-28-1990	Liposome		

Examiner
Signature

Elion Ouehass

Date
Considered

11/16/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 3

Complete if Known

Application Number	10/566,823
Filing Date	Herewith
First Named Inventor	Ping Wang
Art Unit	To Be Determined
Examiner Name	To Be Determined
Attorney Docket Number	KLBS0009-100

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
JO	AD	Anthony et al., "Comprehensive Determinant Mapping of the Hepatitis C-Specific CD8 Cell Repertoire Reveals Unpredicted Immune Hierarchy," <i>Clinical Immunology</i> , (2002) 103(3):264-276.	
	AE	Celis, "Getting peptide vaccines to work; just a matter of quality control?" <i>J. Clin. Invest.</i> (2002) 110:1765-1768.	
	AF	He et al., "Quantitative analysis of hepatitis C Virus-specific CD8+ T cells in peripheral blood and liver using peptide-MHC tetramers," <i>Proc. Nat'l. Acad. Sci.</i> , (1999) 96:5692-5697.	
	AG	Kaul et al., "CD8+ lymphocytes respond to different HIV epitopes in seronegative and infected subjects," <i>Journal of Clinical Investigation</i> (2001) 107(10):1303-1310.	
	AH	Koziel et al., "Hepatitis C Virus (HCV)-Specific Cytotoxic T Lymphocytes Recognize Epitopes in the Core and Envelope Proteins of HCV," <i>Journal of Virology</i> , (1993) 67(12):7522-7532.	
	AI	Li et al., "Peptide-bound Major Histocompatibility Complex Class I Molecules Associate with Tapasin before Dissociation from transporter Associated with Antigen Processing," <i>Journal of Biological Chemistry</i> , (1999) 274(13):8649-8654.	
	AJ	Li et al., "Cytokine-induced Src Homology 2 Protein (CIS) Promotes T cell Receptor-mediated Proliferation and Prolongs Survival of Activated T Cells," <i>J. Exp. Med.</i> , (2000) 191(6):985-994.	
	AK	Li et al., "Cloning and functional characterization of a subunit of the transporter associated with antigen processing," <i>Proc. Nat'l. Acad. Sci.</i> , (1997) 94:8708-8713.	
	AL	Li et al., "Tapasin is Required for Efficient Peptide Binding to Transporter Associated with Antigen Processing," <i>Journal of Biological Chemistry</i> , (2000) 275(3):1581-1586.	
	AM	Mallet-Designé, "Detection of Low-Avidity CD4+ T Cells Using Recombinant Artificial APC: Following the Antivalbumin Immune Response," <i>Journal of Immunology</i> , (2003) 170:123-131.	
JO	AN	Paulsson et al., "Distinct differences in association of MHC class I with endoplasmic reticulum proteins in wild-type, and β 2-microglobulin- and TAP-deficient cell lines," <i>International Immunology</i> , (2001) 13(8):1063-1073.	

Examiner
Signature

Ilion Anspach

Date
Considered

11/16/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/566,823		
		Filing Date	Herewith		
		First Named Inventor	Ping Wang		
		Art Unit	To Be Determined		
		Examiner Name	To Be Determined		
Sheet	3	of	3	Attorney Docket Number	KLBS0009-100

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
JO	AO	Paulsson et al., "Association of Tapasin and COPI Provides a Mechanism for the Retrograde Transport of Major Histocompatibility Complex (MHC) Class I Molecules from the Golgi Complex to the Endoplasmic Reticulum," <i>Journal of Biological Chemistry</i> (2002) 277(21):18266-18271.	
	AP	Paulsson et al., "Assembly of tapasin-associated MHC class I in the absence of the transporter associated with antigen processing (TAP)," <i>International Immunology</i> , (2001) 13(1):23-29.	
	AQ	Saraste et al., "Temperature-sensitive steps in the transport of secretory proteins through the Golgi complex in exocrine pancreatic cells," <i>Proc Natl Acad Sci USA</i> (1986) 83(17):6425-6429.	
	AR	Tartour et al., "Development of non-live vectors and procedures (liposomes, pseudo-viral particles, toxin, beads, adjuvants...) as tools for cancer vaccines," <i>Immunology Letters</i> (2000) 74(1):45-50.	
JO	AS	Wang et al., "Binding of H-2Kb-specific Peptides to TAP and major Histocompatibility Complex Class I in Microsomes from Wild-type, TAP1, and β 2-Microglobulin Mutant Mice," <i>Journal of Biological Chemistry</i> , (1996) 271(40):24830-24835.	

Examiner Signature	<i>Eric Oesper</i>	Date Considered	11/16/07
-----------------------	--------------------	--------------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.